These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

757 related articles for article (PubMed ID: 22999717)

  • 1. A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation).
    Kim BK; Hong MK; Shin DH; Nam CM; Kim JS; Ko YG; Choi D; Kang TS; Park BE; Kang WC; Lee SH; Yoon JH; Hong BK; Kwon HM; Jang Y;
    J Am Coll Cardiol; 2012 Oct; 60(15):1340-8. PubMed ID: 22999717
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal duration of dual antiplatelet therapy following treatment with the endeavor zotarolimus-eluting stent in real-world Japanese patients with coronary artery disease (OPERA): study design and rationale.
    Nakamura M; Nanto S; Hirayama A; Takayama T; Nishikawa M; Kimura K; Morita S; Aizawa T; Asano R; Matsumaru Y; Hamada C; Isshiki T;
    Catheter Cardiovasc Interv; 2014 Sep; 84(3):368-74. PubMed ID: 24382824
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is Bare-Metal Stent Implantation Still Justifiable in High Bleeding Risk Patients Undergoing Percutaneous Coronary Intervention?: A Pre-Specified Analysis From the ZEUS Trial.
    Ariotti S; Adamo M; Costa F; Patialiakas A; Briguori C; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Ferlini M; Vranckx P; Valgimigli M;
    JACC Cardiovasc Interv; 2016 Mar; 9(5):426-36. PubMed ID: 26965932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical outcome following stringent discontinuation of dual antiplatelet therapy after 12 months in real-world patients treated with second-generation zotarolimus-eluting resolute and everolimus-eluting Xience V stents: 2-year follow-up of the randomized TWENTE trial.
    Tandjung K; Sen H; Lam MK; Basalus MWZ; Louwerenburg JHW; Stoel MG; van Houwelingen KG; de Man FHAF; Linssen GCM; Saïd SAM; Nienhuis MB; Löwik MM; Verhorst PMJ; van der Palen J; von Birgelen C
    J Am Coll Cardiol; 2013 Jun; 61(24):2406-2416. PubMed ID: 23602769
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zotarolimus-eluting versus bare-metal stents in uncertain drug-eluting stent candidates.
    Valgimigli M; Patialiakas A; Thury A; McFadden E; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C;
    J Am Coll Cardiol; 2015 Mar; 65(8):805-815. PubMed ID: 25720624
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized comparison of Zotarolimus-Eluting Endeavor Sprint versus bare-metal stent implantation in uncertain drug-eluting stent candidates: rationale, design, and characterization of the patient population for the Zotarolimus-eluting Endeavor Sprint stent in uncertain DES candidates study.
    Valgimigli M; Patialiakas A; Thury A; Colangelo S; Campo G; Tebaldi M; Ungi I; Tondi S; Roffi M; Menozzi A; de Cesare N; Garbo R; Meliga E; Testa L; Gabriel HM; Airoldi F; Ferlini M; Liistro F; Dellavalle A; Vranckx P; Briguori C
    Am Heart J; 2013 Nov; 166(5):831-8. PubMed ID: 24176438
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two-year outcomes after first- or second-generation drug-eluting or bare-metal stent implantation in all-comer patients undergoing percutaneous coronary intervention: a pre-specified analysis from the PRODIGY study (PROlonging Dual Antiplatelet Treatment After Grading stent-induced Intimal hyperplasia studY).
    Valgimigli M; Tebaldi M; Borghesi M; Vranckx P; Campo G; Tumscitz C; Cangiano E; Minarelli M; Scalone A; Cavazza C; Marchesini J; Parrinello G;
    JACC Cardiovasc Interv; 2014 Jan; 7(1):20-8. PubMed ID: 24332420
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Optimized duration of clopidogrel therapy following treatment with the Endeavor zotarolimus-eluting stent in real-world clinical practice (OPTIMIZE) trial: rationale and design of a large-scale, randomized, multicenter study.
    Feres F; Costa RA; Bhatt DL; Leon MB; Botelho RV; King SB; de Paula JE; Mangione JA; Salvadori D; Gusmão MO; Castello H; Nicolela E; Perin MA; Devito FS; Marin-Neto JA; Abizaid A
    Am Heart J; 2012 Dec; 164(6):810-6.e3. PubMed ID: 23194480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Second-generation drug-eluting stent implantation followed by 6- versus 12-month dual antiplatelet therapy: the SECURITY randomized clinical trial.
    Colombo A; Chieffo A; Frasheri A; Garbo R; Masotti-Centol M; Salvatella N; Oteo Dominguez JF; Steffanon L; Tarantini G; Presbitero P; Menozzi A; Pucci E; Mauri J; Cesana BM; Giustino G; Sardella G
    J Am Coll Cardiol; 2014 Nov 18-25; 64(20):2086-97. PubMed ID: 25236346
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lack of association between dual antiplatelet therapy use and stent thrombosis between 1 and 12 months following resolute zotarolimus-eluting stent implantation.
    Silber S; Kirtane AJ; Belardi JA; Liu M; Brar S; Rothman M; Windecker S
    Eur Heart J; 2014 Aug; 35(29):1949-56. PubMed ID: 24510638
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Late-term clinical outcomes with zotarolimus- and sirolimus-eluting stents. 5-year follow-up of the ENDEAVOR III (A Randomized Controlled Trial of the Medtronic Endeavor Drug [ABT-578] Eluting Coronary Stent System Versus the Cypher Sirolimus-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions).
    Kandzari DE; Mauri L; Popma JJ; Turco MA; Gurbel PA; Fitzgerald PJ; Leon MB
    JACC Cardiovasc Interv; 2011 May; 4(5):543-50. PubMed ID: 21596327
    [TBL] [Abstract][Full Text] [Related]  

  • 12. 2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.
    Byrne RA; Kastrati A; Tiroch K; Schulz S; Pache J; Pinieck S; Massberg S; Seyfarth M; Laugwitz KL; Birkmeier KA; Schömig A; Mehilli J;
    J Am Coll Cardiol; 2010 Jun; 55(23):2536-43. PubMed ID: 20417052
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A randomized controlled trial in second-generation zotarolimus-eluting Resolute stents versus everolimus-eluting Xience V stents in real-world patients: the TWENTE trial.
    von Birgelen C; Basalus MW; Tandjung K; van Houwelingen KG; Stoel MG; Louwerenburg JH; Linssen GC; Saïd SA; Kleijne MA; Sen H; Löwik MM; van der Palen J; Verhorst PM; de Man FH
    J Am Coll Cardiol; 2012 Apr; 59(15):1350-61. PubMed ID: 22341737
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial.
    Leon MB; Nikolsky E; Cutlip DE; Mauri L; Liberman H; Wilson H; Patterson J; Moses J; Kandzari DE;
    JACC Cardiovasc Interv; 2010 Oct; 3(10):1043-50. PubMed ID: 20965463
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modifying effect of dual antiplatelet therapy on incidence of stent thrombosis according to implanted drug-eluting stent type.
    Camenzind E; Boersma E; Wijns W; Mauri L; Rademaker-Havinga T; Ordoubadi FF; Suttorp MJ; Al Kurdi M; Steg PG;
    Eur Heart J; 2014 Aug; 35(29):1932-48. PubMed ID: 24627416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of six-month dual antiplatelet therapy after second-generation drug-eluting stent implantation: OPTIMA-C Randomised Clinical Trial and OCT Substudy.
    Lee BK; Kim JS; Lee OH; Min PK; Yoon YW; Hong BK; Shin DH; Kang TS; Kim BO; Cho DK; Jeon DW; Woo SI; Choi S; Kim YH; Kang WC; Kim S; Kim BK; Hong MK; Jang Y; Kwon HM
    EuroIntervention; 2018 Mar; 13(16):1923-1930. PubMed ID: 29104179
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 6- versus 24-month dual antiplatelet therapy after implantation of drug-eluting stents in patients nonresistant to aspirin: the randomized, multicenter ITALIC trial.
    Gilard M; Barragan P; Noryani AAL; Noor HA; Majwal T; Hovasse T; Castellant P; Schneeberger M; Maillard L; Bressolette E; Wojcik J; Delarche N; Blanchard D; Jouve B; Ormezzano O; Paganelli F; Levy G; Sainsous J; Carrie D; Furber A; Berland J; Darremont O; Le Breton H; Lyuycx-Bore A; Gommeaux A; Cassat C; Kermarrec A; Cazaux P; Druelles P; Dauphin R; Armengaud J; Dupouy P; Champagnac D; Ohlmann P; Endresen K; Benamer H; Kiss RG; Ungi I; Boschat J; Morice MC
    J Am Coll Cardiol; 2015 Mar; 65(8):777-786. PubMed ID: 25461690
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A randomized comparison of platinum chromium-based everolimus-eluting stents versus cobalt chromium-based Zotarolimus-Eluting stents in all-comers receiving percutaneous coronary intervention: HOST-ASSURE (harmonizing optimal strategy for treatment of coronary artery stenosis-safety & effectiveness of drug-eluting stents & anti-platelet regimen), a randomized, controlled, noninferiority trial.
    Park KW; Kang SH; Kang HJ; Koo BK; Park BE; Cha KS; Rhew JY; Jeon HK; Shin ES; Oh JH; Jeong MH; Kim S; Hwang KK; Yoon JH; Lee SY; Park TH; Moon KW; Kwon HM; Hur SH; Ryu JK; Lee BR; Park YW; Chae IH; Kim HS;
    J Am Coll Cardiol; 2014 Jul; 63(25 Pt A):2805-16. PubMed ID: 24814486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Three-month dual antiplatelet therapy after implantation of zotarolimus-eluting stents: the DATE (Duration of Dual Antiplatelet Therapy AfterImplantation of Endeavor Stent) registry.
    Hahn JY; Song YB; Choi JH; Choi SH; Lee SY; Park HS; Hur SH; Lee S; Han KR; Rha SW; Cho BR; Park JS; Yoon J; Lim DS; Lee SH; Gwon HC;
    Circ J; 2010 Nov; 74(11):2314-21. PubMed ID: 20938098
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of dual antiplatelet therapy after implantation of the first-generation and second-generation drug-eluting stents.
    Yu X; Chen F; He J; Gao Y; Wu C; Luo Y; Zhang X; Zhang Y; Ren X; Lv S
    Coron Artery Dis; 2013 May; 24(3):217-23. PubMed ID: 23425771
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.